RT Journal Article
SR Electronic
T1 Heritability enrichment implicates microglia in Parkinson’s disease pathogenesis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.25.20238162
DO 10.1101/2020.11.25.20238162
A1 Maren Stolp Andersen
A1 Sara Bandres-Ciga
A1 Regina H. Reynolds
A1 John Hardy
A1 Mina Ryten
A1 Lynne Krohn
A1 Ziv Gan-Or
A1 Inge R. Holtman
A1 International Parkinson’s Disease Genomics Consortium
A1 Lasse Pihlstrøm
YR 2020
UL http://medrxiv.org/content/early/2020/11/29/2020.11.25.20238162.abstract
AB Objective Understanding how different parts of the immune system contribute to pathogenesis in Parkinson’s disease is a burning challenge with important therapeutic implications. We studied enrichment of common variant heritability for Parkinson’s disease stratified by immune and brain cell types.Methods We used summary statistics from the most recent meta-analysis of genome-wide association studies in Parkinson’s disease and partitioned heritability using linkage disequilibrium score regression, stratified for specific cell types as defined by open chromatin regions. We also validated enrichment results using a polygenic risk score approach and intersected disease-associated variants with epigenetic data and expression quantitative loci to nominate and explore a putative microglial locus.Results We found significant enrichment of Parkinson’s disease risk heritability in open chromatin regions of microglia and monocytes. Genomic annotations overlapped substantially between these two cell types, and only the enrichment signal for microglia remained significant in a joint model. We present evidence suggesting P2RY12, a key microglial gene and target for the anti-thrombotic agent clopidogrel, as the likely driver of a significant Parkinson’s disease association signal on chromosome 3.Interpretation Our results provide further support for the importance of immune mechanisms in PD pathogenesis, highlight microglial dysregulation as a contributing etiological factor and nominate a targetable microglial gene candidate as a pathogenic player. Immune processes can be modulated by therapy, with potentially important clinical implications for future treatment in Parkinson’s disease.Competing Interest StatementDr. Pihlstrom reports grants from Norwegian Health Association, from South-Eastern Regional Health Authority, Norway, during the conduct of the study. Dr. Gan-Or reports personal fees from Idorsia, Neuron23, Handl Therapeutics, Lysosomal Therapeutics Inc., Deerfield, Lighthouse, Prevail Therapeutics, Ono Therapeutics, Denali, and Inception Sciences outside the submitted work. Other authors have nothing to report.Funding StatementMSA was funded by a grant from the South-Eastern Regional Health Authority, Norway. LP is supported by the Norwegian Health association. JH was supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. JH is also supported by the Medical Research Council (award number MR/N026004/1), Wellcome Trust Hardy (award number 202903/Z/16/Z), the Dolby Family Fund, National Institute for Health Research University College London Hospitals Biomedical Research Centre and BRCNIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Norwegian Regional Committee for Medical and Health Research Ethics REK 30552All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics for the dataset excluding participants from 23andMe are available at https://bit.ly/2ofzGrk. The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit https://research.23andme.com/dataset-access/ for more information and to apply to access the data. https://bit.ly/2ofzGrk